130 related articles for article (PubMed ID: 1381438)
21. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.
Kellam P; Boucher CA; Tijnagel JM; Larder BA
J Gen Virol; 1994 Feb; 75 ( Pt 2)():341-51. PubMed ID: 7509370
[TBL] [Abstract][Full Text] [Related]
22. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.
Stürmer M; Staszewski S; Doerr HW; Larder B; Bloor S; Hertogs K
Antimicrob Agents Chemother; 2003 Jan; 47(1):54-61. PubMed ID: 12499169
[TBL] [Abstract][Full Text] [Related]
23. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.
Sheehy N; Desselberger U
J Gen Virol; 1993 Feb; 74 ( Pt 2)():223-8. PubMed ID: 7679140
[TBL] [Abstract][Full Text] [Related]
24. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.
Albert J; Wahlberg J; Lundeberg J; Cox S; Sandström E; Wahren B; Uhlén M
J Virol; 1992 Sep; 66(9):5627-30. PubMed ID: 1380098
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
[TBL] [Abstract][Full Text] [Related]
26. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
Welles SL; Pitt J; Colgrove R; McIntosh K; Chung PH; Colson A; Lockman S; Fowler MG; Hanson C; Landesman S; Moye J; Rich KC; Zorrilla C; Japour AJ
AIDS; 2000 Feb; 14(3):263-71. PubMed ID: 10716502
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
[TBL] [Abstract][Full Text] [Related]
29. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants.
Wahlberg J; Fiore J; Angarano G; Uhlén M; Albert J
J Infect Dis; 1994 Mar; 169(3):611-4. PubMed ID: 8158034
[TBL] [Abstract][Full Text] [Related]
30. Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue.
McGavin CH; Land SA; Sebire KL; Hooker DJ; Gurusinghe AD; Birch CJ
AIDS; 1996 Jan; 10(1):47-53. PubMed ID: 8924251
[TBL] [Abstract][Full Text] [Related]
31. Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed.
Cho YK; Sung H; Lee HJ; Joo CH; Cho GJ
Int Immunopharmacol; 2001 Jul; 1(7):1295-1305. PubMed ID: 11460310
[TBL] [Abstract][Full Text] [Related]
32. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.
Cleland A; Watson HG; Robertson P; Ludlam CA; Brown AJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):6-18. PubMed ID: 8624762
[TBL] [Abstract][Full Text] [Related]
33. Sequence analysis of proviral HIV RT amplified directly by a semi-quantitative technique from AZT treated patients.
Stein CA; Levantis P; Oxford JS
J Med Virol; 1994 Oct; 44(2):115-21. PubMed ID: 7531752
[TBL] [Abstract][Full Text] [Related]
34. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
35. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy.
Loveday C; Kaye S; Tenant-Flowers M; Semple M; Ayliffe U; Weller IV; Tedder RS
Lancet; 1995 Apr; 345(8953):820-4. PubMed ID: 7534858
[TBL] [Abstract][Full Text] [Related]
37. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance.
Kellam P; Larder BA
J Virol; 1995 Feb; 69(2):669-74. PubMed ID: 7529334
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
García-Lerma JG; Nidtha S; Heneine W
J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
[TBL] [Abstract][Full Text] [Related]
39. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
Coakley EP; Gillis JM; Hammer SM
AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
[TBL] [Abstract][Full Text] [Related]
40. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
